Volume 7: Issue 2

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

Vallerie V. McLaughlin, MD, SLC Chair, University of Michigan Health System, Ann Arbor, Michigan
David B. Badesch, MD, SLC Immediate Past Chair, University of Colorado Health Sciences Center, Denver, Colorado
John H. Newman, MD, SLC Chair Elect, Vanderbilt Medical School, Nashville, Tennessee
Robyn J. Barst, MD, New York, New York
Raymond L. Benza, MD, University of Alabama Health System, Birmingham, Alabama
Todd Bull, MD, University of Colorado Health Sciences Center,

Raj S. Kasthuri, MD

Download as Powerpoint
Download Figure

Robert A. S. Roubey, MD

Download as Powerpoint
Download Figure

Antiphospholipid antibodies (aPL) have been implicated in the development of both idiopathic pulmonary arterial hypertension (PAH) and PAH associated with connective tissue disease (CTD) and chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary venous hypertension (PVH) can also develop as a sequela of aPL-associated valvular heart disease (Libman-Sacks endocarditis).

Antiphospholipid antibodies are a group of autoantibodies with an apparent specificity for anionic phospholipids. In the clinical laboratory, aPL are typically detected in anticardiolipin assays and by their ability to prolong coagulation tests

This discussion was moderated by Harrison (Hap) Farber, MD, Professor, Department of Medicine, Boston University School of Medicine, and Director, Pulmonary Hypertension Center, Boston Medical Center, Boston, Massachusetts. Panel members included Richard M. Silver, MD, Professor of Medicine and Pediatrics and Director of the Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina; Virginia D. Steen, MD, Proffessor of Medicine, Georgetown University, Washington, DC; and Charles Strange, MD, Professor of Pulmonary Medicine, Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina.

Targeting the Connection Between PAH and Connecive Tissue Disease

Highlighting Current and Future Perspectives in the Journal

The Scientific Leadership Council of the Pulmonary Hypertension Association

Virginia D. Steen, MD: Pushing the Envelope of Research, Redefining the Link Between Scleroderma and PAH

Pulmonary Hypertension in Systemic Lupus Erythematosus

Pulmonary Hypertension and the Antiphospholipid Syndrome

Scleroderma Associated Pulmonary Hypertension

Epidemiology

Pulmonary Arterial Hypertension Associated With Scleroderma

Combination Therapy in Pulmonary Artery Hypertension

Conference Abstracts

Guest Editor’s Memo

A Roundtable Discussion Addressing Patient-Centered Care and Quality of Life in Patients With Pulmonary Arterial Hypertension

Editor’s Memo

Pulmonary Hypertension Associated With Parenchymal Lung Disease